Haemonetics Corporation

63.01
-1.20 (-1.87%)
At close: Mar 28, 2025, 3:59 PM
63.19
0.29%
After-hours: Mar 28, 2025, 05:31 PM EDT

Haemonetics Statistics

Share Statistics

Haemonetics has 50.24M shares outstanding. The number of shares has increased by -1.11% in one year.

Shares Outstanding 50.24M
Shares Change (YoY) -1.11%
Shares Change (QoQ) -1.86%
Owned by Institutions (%) 99.99%
Shares Floating 49.68M
Failed to Deliver (FTD) Shares 6.56K
FTD / Avg. Volume 0.7%

Short Selling Information

The latest short interest is 4.96M, so 9.88% of the outstanding shares have been sold short.

Short Interest 4.96M
Short % of Shares Out 9.88%
Short % of Float 9.99%
Short Ratio (days to cover) 10.74

Valuation Ratios

The PE ratio is 36.81 and the forward PE ratio is 13.06. Haemonetics's PEG ratio is 16.71.

PE Ratio 36.81
Forward PE 13.06
PS Ratio 3.31
Forward PS 2
PB Ratio 4.51
P/FCF Ratio 37.48
PEG Ratio 16.71
Financial Ratio History

Enterprise Valuation

Haemonetics Corporation has an Enterprise Value (EV) of 4.68B.

EV / Earnings 39.84
EV / Sales 3.58
EV / EBITDA 17.64
EV / EBIT 28.41
EV / FCF 40.57

Financial Position

The company has a current ratio of 2.56, with a Debt / Equity ratio of 0.84.

Current Ratio 2.56
Quick Ratio 1.5
Debt / Equity 0.84
Total Debt / Capitalization 45.7
Cash Flow / Debt 0.22
Interest Coverage 12.67

Financial Efficiency

Return on equity (ROE) is 0.12% and return on capital (ROIC) is 7.22%.

Return on Equity (ROE) 0.12%
Return on Assets (ROA) 0.05%
Return on Capital (ROIC) 7.22%
Revenue Per Employee $357,958.71
Profits Per Employee $32,146.02
Employee Count 3,657
Asset Turnover 0.6
Inventory Turnover 1.95

Taxes

Income Tax 34.31M
Effective Tax Rate 0.23

Stock Price Statistics

The stock price has increased by -24.82% in the last 52 weeks. The beta is 0.43, so Haemonetics's price volatility has been higher than the market average.

Beta 0.43
52-Week Price Change -24.82%
50-Day Moving Average 66.5
200-Day Moving Average 77.25
Relative Strength Index (RSI) 44.03
Average Volume (20 Days) 942.64K

Income Statement

In the last 12 months, Haemonetics had revenue of 1.31B and earned 117.56M in profits. Earnings per share was 2.32.

Revenue 1.31B
Gross Profit 691.55M
Operating Income 164.88M
Net Income 117.56M
EBITDA 265.58M
EBIT 164.88M
Earnings Per Share (EPS) 2.32
Full Income Statement

Balance Sheet

The company has 178.8M in cash and 807.79M in debt, giving a net cash position of -628.99M.

Cash & Cash Equivalents 178.8M
Total Debt 807.79M
Net Cash -628.99M
Retained Earnings 360.46M
Total Assets 2.53B
Working Capital 752.63M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 181.75M and capital expenditures -66.3M, giving a free cash flow of 115.45M.

Operating Cash Flow 181.75M
Capital Expenditures -66.3M
Free Cash Flow 115.45M
FCF Per Share 2.28
Full Cash Flow Statement

Margins

Gross margin is 52.83%, with operating and profit margins of 12.6% and 8.98%.

Gross Margin 52.83%
Operating Margin 12.6%
Pretax Margin 11.6%
Profit Margin 8.98%
EBITDA Margin 20.29%
EBIT Margin 12.6%
FCF Margin 8.82%

Dividends & Yields

HAE does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield 3.62%
FCF Yield 3.58%
Dividend Details

Analyst Forecast

The average price target for HAE is $104, which is 62.1% higher than the current price. The consensus rating is "Buy".

Price Target $104
Price Target Difference 62.1%
Analyst Consensus Buy
Analyst Count 9
Stock Forecasts

Stock Splits

The last stock split was on Dec 3, 2012. It was a forward split with a ratio of 2:1.

Last Split Date Dec 3, 2012
Split Type forward
Split Ratio 2:1

Scores

Altman Z-Score 2.56
Piotroski F-Score 6